Evan T. Hall, MD, of Fred Hutchinson Cancer Center, discusses findings from the randomized phase II MATRiX trial, which evaluated the efficacy of the ATR inhibitor tuvusertib with or without avelumab in patients with anti–PD-(L)1–refractory Merkel cell carcinoma (Abstract LBA9514).
Krishnan R. Patel, MD, of the National Cancer Institute, discusses a combined analysis of the NRG/RTOG 9202, 9413, 9902, and 0521 trials that looked at using clinico-transcriptomic risk stratification to guide abiraterone treatment intensification among patients with high-risk prostate cancer (Abstract 5000).
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, presents findings from a retrospective cohort study which used a large U.S. database to evaluate clinical outcomes among Medicare beneficiaries treated with first-line therapy for chronic lymphocytic leukemia (CLL) (Abstract 7047).
To learn more about this data, read a related article in Oncology and Therapy.
Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute, reviews the results of a large clinicogenomic database study that looked at overall survival by genomic profile among patients with HER2-positive metastatic breast cancer. Patients with mutations in key DNA repair genes experienced a numerically worse prognosis, representing an unmet need for drug development, say researchers (Abstract 1045).
John M. Burke, MD, of SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, presents findings from the phase III frontMIND trial, which evaluated tafasitamab plus lenalidomide and R-CHOP in patients newly diagnosed with diffuse large B-cell lymphoma (Abstract LBA7000).
Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses findings from ECOG-ACRIN EA5142/ALCHEMIST, a phase III randomized trial that evaluated the efficacy of adjuvant nivolumab after standard-of-care adjuvant therapy in patients with resected lung adenocarcinoma without sensitizing EGFR and ALK alterations and squamous cell carcinoma (Abstract 8000).
